Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Evaluation of the HemoCue WBC DIFF in leukopenic patient samples

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Kur, Dår K ; Agersnap, Niels ; Holländer, Niels Henrik ; Pedersen, Ole B Vesterager ; Friis-Hansen, Lennart. / Evaluation of the HemoCue WBC DIFF in leukopenic patient samples. In: International Journal of Laboratory Hematology (Print Edition). 2020 ; Vol. 42, No. 3. pp. 256-262.

Bibtex

@article{398cbea6a8c54301bb4ee58d6b7056fa,
title = "Evaluation of the HemoCue WBC DIFF in leukopenic patient samples",
abstract = "BACKGROUND: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point-Of-Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC.METHODS: Sysmex samples with WBCs 0.05-3.40 × 109 /L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated.RESULTS: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8-9.2% for total WBC (0.56-2.29 ×109 /L), 8.7-14.3% for neutrophils (0.36-1.33 ×109 /L) and 9.8-15.1% for lymphocytes (0.35-0.89 ×109 /L). The correlation coefficient was between 0.658 and 0.986-poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs.CONCLUSIONS: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia.",
keywords = "HemoCue WBC DIFF, cancer patients, leukopenia, nRBC, neutropenia, sysmex, Leukocyte Count/instrumentation, Leukopenia/blood, Point-of-Care Testing, Humans, Male, Adult, Neoplasms/blood",
author = "Kur, {D{\aa}r K} and Niels Agersnap and Holl{\"a}nder, {Niels Henrik} and Pedersen, {Ole B Vesterager} and Lennart Friis-Hansen",
note = "{\textcopyright} 2020 John Wiley & Sons Ltd.",
year = "2020",
doi = "10.1111/ijlh.13158",
language = "English",
volume = "42",
pages = "256--262",
journal = "International Journal of Laboratory Hematology (Print Edition)",
issn = "1751-5521",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Evaluation of the HemoCue WBC DIFF in leukopenic patient samples

AU - Kur, Dår K

AU - Agersnap, Niels

AU - Holländer, Niels Henrik

AU - Pedersen, Ole B Vesterager

AU - Friis-Hansen, Lennart

N1 - © 2020 John Wiley & Sons Ltd.

PY - 2020

Y1 - 2020

N2 - BACKGROUND: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point-Of-Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC.METHODS: Sysmex samples with WBCs 0.05-3.40 × 109 /L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated.RESULTS: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8-9.2% for total WBC (0.56-2.29 ×109 /L), 8.7-14.3% for neutrophils (0.36-1.33 ×109 /L) and 9.8-15.1% for lymphocytes (0.35-0.89 ×109 /L). The correlation coefficient was between 0.658 and 0.986-poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs.CONCLUSIONS: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia.

AB - BACKGROUND: White blood cell (WBC) counts are used to monitor bone marrow function and to screen for infections. The HemoCue WBC DIFF Point-Of-Care (POC) instrument classifies WBCs through cell image recognition. To evaluate its suitability for monitoring cancer patients, we examined its performance in samples from patient with leukopenia and in samples containing nRBC.METHODS: Sysmex samples with WBCs 0.05-3.40 × 109 /L were examined on the HemoCue WBC DIFF, and the correlations between the instruments were assessed by Deming regression for total WBC, neutrophils, and lymphocytes. The theoretical CV% (CVt), calculated from number of cells counted by the HemoCue WBC DIFF, was used to determine the statistical error of the WBC counts. The interference of nRBC was also evaluated.RESULTS: The counting variation was primarily the source of statistical error in the lower counts with an imprecision between 3.8-9.2% for total WBC (0.56-2.29 ×109 /L), 8.7-14.3% for neutrophils (0.36-1.33 ×109 /L) and 9.8-15.1% for lymphocytes (0.35-0.89 ×109 /L). The correlation coefficient was between 0.658 and 0.986-poorest for lymphocytes. The total WBC count on the HemoCue WBC DIFF was significantly increased in nRBC samples due to lymphocyte count overestimation, and not by other WBCs.CONCLUSIONS: The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia.

KW - HemoCue WBC DIFF

KW - cancer patients

KW - leukopenia

KW - nRBC

KW - neutropenia

KW - sysmex

KW - Leukocyte Count/instrumentation

KW - Leukopenia/blood

KW - Point-of-Care Testing

KW - Humans

KW - Male

KW - Adult

KW - Neoplasms/blood

UR - http://www.scopus.com/inward/record.url?scp=85079423002&partnerID=8YFLogxK

U2 - 10.1111/ijlh.13158

DO - 10.1111/ijlh.13158

M3 - Journal article

C2 - 32039560

VL - 42

SP - 256

EP - 262

JO - International Journal of Laboratory Hematology (Print Edition)

JF - International Journal of Laboratory Hematology (Print Edition)

SN - 1751-5521

IS - 3

ER -

ID: 60300191